Blog
17 Articles
Research
June 27, 2017 • 2 Min
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Research
August 18, 2016 • 2 Min
Exploring the Effectiveness of an Experimental Class of Drug
Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?